Related Experiment Video

Updated: Jul 6, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

Understanding the role of genetic polymorphisms in chronic kidney disease

Karin Luttropp1, Peter Stenvinkel, Juan Jesús Carrero

  • 1Department of Molecular Medicine and Surgery, Neurogenetics Unit, Karolinska Institutet, Stockholm, Sweden.

Pediatric Nephrology (Berlin, Germany)
|March 28, 2008
PubMed

Insights

The global prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) is rising, particularly in pediatric patients. Genetic factors may play a role in CKD progression, necessitating genetic screening for personalized treatment.

Area of Science:

  • Nephrology
  • Genetics
  • Pediatrics

Background:

  • Global prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) is increasing.
  • Improved renal replacement therapy (RRT) access and survival rates contribute to rising CKD/ESRD numbers.
  • While environmental factors are primary drivers, genetic factors may influence CKD incidence and progression.

Purpose of the Study:

  • To understand the pathogenesis and underlying causes of CKD in pediatric patients.
  • To identify genetic factors contributing to CKD outcomes and complications.
  • To explore the potential for genetic screening to predict disease, identify at-risk populations, and enable personalized therapy.

Main Methods:

  • The study focuses on the genetic analysis of pediatric CKD patients.
  • Investigates the influence of genetic factors in the context of a uraemic environment.
  • Emphasizes the importance of genetic screening in this specific patient group.

Main Results:

  • No definitive studies show increasing/decreasing pediatric CKD patient numbers.
  • Genetic factors are hypothesized to influence CKD incidence and progression.
  • Paediatric CKD patients may exhibit heightened sensitivity to genetic effects due to the uraemic milieu.

Conclusions:

  • Genetic screening in pediatric CKD patients can enhance preventive measures and improve outcomes.
  • Understanding genetic backgrounds may lead to individualized therapeutic strategies.
  • Further research into genetic factors is crucial for advancing CKD management in children.

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...